LNSR Quote, Financials, Valuation and Earnings

Ainos has a net margin of -11.09% compared to LENSAR's net margin of -15991.17%. LENSAR's return on equity of -56.16% beat Ainos's return on equity of -52.95%.

LENSAR has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that LENSAR has higher upside potential than Ainos, analysts believe LENSAR is more attractive than Ainos.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.704%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $13.5M, which are larger than Ainos quarterly revenues of $20.7K. LENSAR's net income of -$1.5M is higher than Ainos's net income of -$3.7M. Notably, LENSAR's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.03x versus 34.77x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -11.09% compared to LENSAR's net margin of -307.88%. LENSAR's return on equity of -56.16% beat Intelligent Bio Solutions's return on equity of -176.44%.

LENSAR has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 782.35%. Given that Intelligent Bio Solutions has higher upside potential than LENSAR, analysts believe Intelligent Bio Solutions is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $13.5M, which are larger than Intelligent Bio Solutions quarterly revenues of $872.3K. LENSAR's net income of -$1.5M is higher than Intelligent Bio Solutions's net income of -$2.7M. Notably, LENSAR's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.03x versus 0.63x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -11.09% compared to LENSAR's net margin of -59.9%. LENSAR's return on equity of -56.16% beat Standard BioTools's return on equity of -48.03%.

LENSAR has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 68.49%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.606, suggesting its more volatile than the S&P 500 by 60.617%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $13.5M, which are smaller than Standard BioTools quarterly revenues of $45M. LENSAR's net income of -$1.5M is higher than Standard BioTools's net income of -$26.9M. Notably, LENSAR's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.03x versus 3.28x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of -11.09% compared to LENSAR's net margin of -95.71%. LENSAR's return on equity of -56.16% beat Zomedica's return on equity of -27.17%.

LENSAR has a consensus price target of --, signalling upside risk potential of 26.58%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 108.33%. Given that Zomedica has higher upside potential than LENSAR, analysts believe Zomedica is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $13.5M, which are larger than Zomedica quarterly revenues of $7M. LENSAR's net income of -$1.5M is higher than Zomedica's net income of -$6.7M. Notably, LENSAR's price-to-earnings ratio is -- while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.03x versus 4.40x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.